Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








TB-Related Articles						Print
													Updated January 30, 2024
																	Related Pages
										Return to Main Menu**2023 DTBE Publications**
Adams T, Miller K, Law M, Pitcher E, Chinpar B, White K, Deutsch-Feldman M, Li R, Filardo TD, Romieu-Hernandez AC, Schwartz NG, Haddad MB, Glowicz J. Systematic contact investigation: an essential infection prevention skill to prevent tuberculosis transmission in healthcare settings. Am J Infect Control. 2023 Jun 22:S0196-6553(23)00478-9. doi: 10.1016/j.ajic.2023.06.014. Epub ahead of print. PMID: 37355098.
Adekoya N, Chang MH, Wortham J, Truman BI. Disparities in Rates of Death From HIV or Tuberculosis Before Age 65 Years, by Race, Ethnicity, and Sex, United States, 2011-2020. Public Health Rep. 2023 Dec 18:333549231213328. doi: 10.1177/00333549231213328. Epub ahead of print. PMID: 38111105.
Baker JJ, Nahar R, Petroelje BK, Goswami ND, Lardizabal AA. Fluoroquinolone-resistant latent tuberculosis infection: A literature review and case series of 5 patients treated with linezolid monotherapy. J Clin Tuberc Other Mycobact Dis. 2023 May 18;32:100376. doi: 10.1016/j.jctube.2023.100376. PMID: 37252368; PMCID: PMC10209533.
Caruso E, Mangan JM, Maiuri A, Bouwkamp B, DeLuca N. Tuberculosis Testing and Latent Tuberculosis Infection Treatment Practices Among Health Care Providers – United States, 2020-2022. MMWR Morb Mortal Wkly Rep. 2023 Nov 3;72(44):1183-1189. doi: 10.15585/mmwr.mm7244a2. PMID: 37917562; PMCID: PMC10629750.
Chorba T. Ars longa, vita brevis. Emerg Infect Dis. 2023 Mar;29(3):674-675. https://dx.doi.org/10.3201/eid2903.ac2903.
Feng PI, Horne DJ, Wortham JM, Katz DJ; CDC Tuberculosis Epidemiologic Studies Consortium. Trends in tuberculosis clinicians’ adoption of short-course regimens for latent tuberculosis infection. J Clin Tuberc Other Mycobact Dis. 2023 Jun 13;33:100382. doi: 10.1016/j.jctube.2023.100382. PMID: 37416302; PMCID: PMC10320582.
Frazier C, Nabity SA, Flood J. Incidence of TB disease among persons who use drugs in California. Int J Tuberc Lung Dis. 2023 Oct 1;27(10):781-783. doi: 10.5588/ijtld.23.0228. PMID: 37749841; PMCID: PMC10519387.
Groenweghe E, Swensson L, Winans KD, Griffin P, Haddad MB, Brostrom RJ, Tuckey D, Lam CK, Armitige LY, Seaworth BJ, Corriveau EA. Outbreak of Multidrug-Resistant Tuberculosis – Kansas, 2021-2022. MMWR Morb Mortal Wkly Rep. 2023 Sep 1;72(35):957-960. doi: 10.15585/mmwr.mm7235a4. PMID: 37651293.
Haley CA, Schechter MC, Ashkin D, Peloquin CA, Cegielski JP, Andrino BB, Burgos M, Caloia LA, Chen L, Colon-Semidey A, DeSilva MB, Dhanireddy S, Dorman SE, Dworkin FF, Hammond-Epstein H, Easton AV, Gaensbauer JT, Ghassemieh B, Gomez ME, Horne D, Jasuja S, Jones BA, Kaplan LJ, Khan AE, Kracen E, Labuda S, Landers KM, Lardizabal AA, Lasley MT, Letzer DM, Lopes VK, Lubelchek RJ, Macias CP, Mihalyov A, Misch EA, Murray JA, Narita M, Nilsen DM, Ninneman MJ, Ogawa L, Oladele A, Overman M, Ray SM, Ritger KA, Rowlinson MC, Sabuwala N, Schiller TM, Schwartz LE, Spitters C, Thomson DB, Tresgallo RR, Valois P, Goswami ND; BPaL Implementation Group. Implementation of BPaL in the United States: Experience using a novel all-oral treatment regimen for treatment of rifampin-resistant or rifampin-intolerant TB disease. Clin Infect Dis. 2023 May 30:ciad312. doi: 10.1093/cid/ciad312. Epub ahead of print. PMID: 37249079.
Kurbatova EV, Phillips PP, Dorman SE, Sizemore EE, Bryant KE, Purfield AE, Ricaldi J, Brown NE, Johnson JL, Wallis CL, Akol JP, Ocheretina O, Van Hung N, Mayanja-Kizza H, Lourens M, Dawson R, Nhung NV, Pierre S, Musodza Y, Shenje J, Badal-Faesen S, Vilbrun SC, Waja Z, Peddareddy L, Scott NA, Yuan Y, Vernon A, Goldberg SV, Swindells S, Chaisson RE, Nahid P; AIDS Clinical Trials Group and the Tuberculosis Trials Consortium. A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase TB Trials. Am J Respir Crit Care Med. 2023 Feb 15. doi: 10.1164/rccm.202206-1118OC. Epub ahead of print. PMID: 36790881.
Labuda SM, Seaworth B, Dasgupta S, Goswami ND; BPaL Accelerated Monitoring Project Team. Bedaquiline, pretomanid, and linezolid with or without moxifloxacin for tuberculosis. Lancet Respir Med. 2023 Nov 30:S2213-2600(23)00426-5. doi: 10.1016/S2213-2600(23)00426-5. Epub ahead of print. PMID: 38043563.
Li R, Deutsch-Feldman M, Adams T, Law M, Biak C, Pitcher E, Drees M, Hernandez-Romieu AC, Filardo TD, Cropper T, Martinez A, Wilson WW, Althomsons SP, Morris SB, Wortham JM, Benowitz I, Schwartz NG, White K, Haddad MB, Glowicz JB; Bone Allograft Tuberculosis Investigators. Transmission of Mycobacterium tuberculosis to healthcare personnel resulting from contaminated bone graft material, United States, June 2021- August 2022. Clin Infect Dis. 2023 Jan 20:ciad029. doi: 10.1093/cid/ciad029. Epub ahead of print. PMID: 36660866.
Mangan JM, Burzynski J, deCastro BR, Salerno MM, Lam CK, Macaraig M, Reaves M, Kiskadden-Bechtel S, Bowers S, Sathi C, Dias MP, Goswami ND, Vernon A. Challenges associated with electronic and in-person directly observed therapy during a randomized trial. Int J Tuberc Lung Dis. 2023 Apr 1;27(4):298-307. doi: 10.5588/ijtld.22.0583. PMID: 37035970.
Mangan JM, Woodruff RS, Winston CA, Nabity SA, Haddad MB, Dixon MG, Parvez FM, Sera-Josef C, Salmon-Trejo LAT, Lam CK. Recommendations for Use of Video Directly Observed Therapy During Tuberculosis Treatment – United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Mar 24;72(12):313-316. doi: 10.15585/mmwr.mm7212a4. PMID: 36952279; PMCID: PMC10042619.
Marks SM, Self JL, Venkatappa T, Wolff MB, Hopkins PB, Augustine RJ, Khan A, Schwartz NG, Schmit KM, Morris SB. Diagnosis, Treatment, and Prevention of Tuberculosis Among People Experiencing Homelessness in the United States: Current Recommendations. Public Health Rep. 2023 Jan 26:333549221148173. doi: 10.1177/00333549221148173. Epub ahead of print. PMID: 36703605.
Marshall KE, Free RJ, Filardo TD, Schwartz NG, Hernandez-Romieu AC, Thacker TC, Lehman KA, Annambhotla P, Dupree PB, Glowicz JB, Scarpita AM, Brubaker SA, Czaja CA, Basavaraju SV. Incomplete tissue product tracing during an investigation of a tissue-derived tuberculosis outbreak. Am J Transplant. 2023 Sep 15:S1600-6135(23)00693-7. doi: 10.1016/j.ajt.2023.09.005. Epub ahead of print. PMID: 37717630.
Miele K, Rock RB, LaCourse SM, Ashkin D, Armitige LY, Pomputius W, Goswami ND. Notes from the Field: Undiagnosed Tuberculosis During Pregnancy Resulting in a Neonatal Death – United States, 2021. MMWR Morb Mortal Wkly Rep. 2023 Dec 8;72(49):1331-1332. doi: 10.15585/mmwr.mm7249a4. PMID: 38060433; PMCID: PMC10715820.
Nabity SA, Marks SM, Goswami ND, Smith SR, Timme E, Price SF, Gross L, Self JL, Toren KG, Narita M, Wegener DH, Wang SH; National Tuberculosis Controllers Association/CDC TB-COVID-19 Collaboration1. Characteristics of and Deaths among 333 Persons with Tuberculosis and COVID-19 in Cross-Sectional Sample from 25 Jurisdictions, United States. Emerg Infect Dis. 2023 Oct;29(10):2016-2023. doi: 10.3201/eid2910.230286. Epub 2023 Aug 30. PMID: 37647628; PMCID: PMC10521611.
Sadowski C, Belknap R, Holland DP, Moro RN, Chen MP, Wright A, Millet JP, Caylà JA, Scott NA, Borisov A, Gandhi NR. Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2023 Jun 16;76(12):2090-2097. doi: 10.1093/cid/ciad083. PMID: 36815322; PMCID: PMC10273365.
Salerno MM, Burzynski J, Mangan JM, Hill A, deCastro BR, Goswami ND, Lam CK, Macaraig M, Schluger NW, Vernon AA. Adverse events among persons with TB using in-person vs. electronic directly observed therapy. Int J Tuberc Lung Dis. 2023 Aug 1;27(11):833-840. doi: 10.5588/ijtld.22.0594. PMID: 37880884.
Schildknecht KR, Pratt RH, Feng PI, Price SF, Self JL. Tuberculosis – United States, 2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 24;72(12):297-303. doi: 10.15585/mmwr.mm7212a1. PMID: 36952282; PMCID: PMC10042618.
Scott NA, Sadowski C, Vernon A, Arevalo B, Beer K, Borisov A, Cayla JA, Chen M, Feng PJ, Moro RN, Holland DP, Martinson N, Millet JP, Miro JM, Belknap R. Using a medication event monitoring system to evaluate self-report and pill count for determining treatment completion with self-administered, once-weekly isoniazid and rifapentine. Contemp Clin Trials. 2023 Jun;129:107173. doi: 10.1016/j.cct.2023.107173. Epub 2023 Mar 31. PMID: 37004811.
Stalter RM, Pecha M, Dov L, Miller D, Ghazal Z, Wortham J, Althomsons S, Deutsch-Feldman M, Stewart R, Felix D, Hsu S, Strick LB. Tuberculosis Outbreak in a State Prison System – Washington, 2021-2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 24;72(12):309-312. doi: 10.15585/mmwr.mm7212a3. PMID: 36952619; PMCID: PMC10042616.
Swartwood NA, Testa C, Cohen T, Marks SM, Hill AN, Beeler Asay G, Cochran J, Cranston K, Randall LM, Tibbs A, Horsburgh CR Jr, Salomon JA, Menzies NA. Tabby2: a user-friendly web tool for forecasting state-level TB outcomes in the United States. BMC Med. 2023 Aug 30;21(1):331. doi: 10.1186/s12916-023-02785-y. PMID: 37649031.
Venkatappa T, Shen D, Ayala A, Li R, Sorri Y, Punnoose R, Katz D; Tuberculosis Epidemiologic Studies Consortium. Association of *Mycobacterium tuberculosis* infection test results with risk factors for tuberculosis transmission. J Clin Tuberc Other Mycobact Dis. 2023 Jun 29;33:100386. doi: 10.1016/j.jctube.2023.100386. PMID: 37426113; PMCID: PMC10328964.
Vonnahme LA, Raykin J, Jones M, Oakley J, Puro J, Langer A, Aiona K, Belknap R, Ayers T, Todd J, Winglee K. Using Electronic Health Record Data to Measure the Latent Tuberculosis Infection Care Cascade in Safety-Net Primary Care Clinics. AJPM Focus. 2023 Sep 28;2(4):100148. doi: 10.1016/j.focus.2023.100148. PMID: 37941821; PMCID: PMC10630620.
Winston CA, Marks SM, Carr W. Estimated Costs of 4-Month Pulmonary Tuberculosis Treatment Regimen, United States. Estimated Costs of 4-Month Pulmonary Tuberculosis Treatment Regimen, United States. Emerg Infect Dis. 2023 Oct;29(10):2102-2104. doi: 10.3201/eid2910.230314. PMID: 37735769; PMCID: PMC10521593.
Winters N, Belknap R, Benedetti A, Borisov A, Campbell JR, Chaisson RE, Chan PC, Martinson N, Nahid P, Scott NA, Sizemore E, Sterling TR, Villarino ME, Wang JY, Menzies D. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. Lancet Respir Med. 2023 Mar 23:S2213-2600(23)00096-6. doi: 10.1016/S2213-2600(23)00096-6. Epub ahead of print. PMID: 36966788.
Winters N, Schnitzer ME, Campbell JR, Ripley S, Winston C, Savic R, Ahmad N, Bisson G, Dheda K, Esmail A, Gegia M, Monedero I, Dalcolmo MP, Rodrigues D, Singla R, Yim JJ, Menzies D. Identifying patients with multidrug-resistant tuberculosis who may benefit from shorter durations of treatment. PLoS One. 2023 Oct 5;18(10):e0292106. doi: 10.1371/journal.pone.0292106. PMID: 37797071.
Zavala S, Winglee K, Ho CS, Pettit AC, Ahmed A, Katz DJ, Belknap RW, Stout JE; Tuberculosis Epidemiologic Studies Consortium. Examining Test Cutoffs to Optimize Diagnosis of Latent Tuberculosis Infection in Non-US-born People. Ann Am Thorac Soc. 2023 May 9. doi: 10.1513/AnnalsATS.202212-1005OC. Epub ahead of print. PMID: 37159954.Year20232022202120202019201820172016201520142013
							
					
							Last Reviewed:  January 30, 2024						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue